Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | FABP3 | P05413 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12630062 | 0.92 | PSIP1 (0.48) | PSIP1KDM4EFABP3FABP4PLA2G2A | |
| SCHEMBL10325642 | 0.88 | PSIP1 (0.59) | PSIP1KDM4EFABP3FABP4PLA2G2A | |
| SCHEMBL29985176 | 0.88 | PSIP1 (0.59) | PSIP1KDM4EFABP3FABP4PLA2G2A | |
| SCHEMBL12630048 | 0.79 | FABP3 (0.56) | PSIP1KDM4EFABP3FABP4 | |
| SCHEMBL12630049 | 0.78 | PSIP1 (0.41) | PSIP1KDM4EFABP3FABP4PLA2G2A | |
| SCHEMBL12630045 | 0.73 | FABP3 (0.53) | PSIP1KDM4EFABP3FABP4PLA2G2A | |
| SCHEMBL12630059 | 0.73 | ALDH1A1 (0.46) | PSIP1KDM4EFABP3FABP4PLA2G2A | |
| SCHEMBL12630004 | 0.72 | PSIP1 (0.42) | PSIP1KDM4EFABP3FABP4PLA2G2A | |
| SCHEMBL6122055 | 0.72 | PSIP1 (1.00) | PSIP1 | |
| SCHEMBL6122448 | 0.72 | PSIP1 (1.00) | PSIP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939545-B2 | additionally comprising at least one other antiviral agent | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-7939545-B2 | additionally comprising at least one other antiviral agent | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| EP-2019825-B9 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2011-01-26 | — | — | EP | disclosed |
| EP-2019825-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2010-09-01 | — | — | EP | disclosed |
| US-20080221159-A1 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221159-A1 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2007131350-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221159-A1 | Inhibitors of human immunodeficiency virus replication | RTF2, RTF1, POLR1E | PSIP1 1908/4885KDM4E 1488/4885FABP3 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.